相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial
Hassan Yaish et al.
HAEMOPHILIA (2020)
WFH Guidelines for the Management of Hemophilia, 3rd edition
Alok Srivastava et al.
HAEMOPHILIA (2020)
The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab
Manuel Carcao et al.
HAEMOPHILIA (2019)
Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS)
Johnny Mahlangu et al.
HAEMOPHILIA (2019)
Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A
H. Marijke van den Berg et al.
BLOOD (2019)
Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A
Delphine Bachelet et al.
PLOS ONE (2019)
Interim Analysis of the Extension Study with rVIII-SingleChain in Previously Untreated Patients (PUPs) with Severe Hemophilia A (CSL627-3001)
Elena Santagostino et al.
BLOOD (2019)
Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program
Toshko Lissitchkov et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2019)
Inhibitors: A Need for Eradication?
Elena Santagostino et al.
ACTA HAEMATOLOGICA (2019)
Immunogenicity, efficacy and safety of Nuwiq((R)) (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study
R. J. Liesner et al.
HAEMOPHILIA (2018)
Risk factors for inhibitor development in severe hemophilia a
Isabella Garagiola et al.
THROMBOSIS RESEARCH (2018)
Product type and other environmental risk factors for inhibitor development in severe hemophilia A
Flora Peyvandi et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2018)
Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?
Kenneth Lieuw
JOURNAL OF BLOOD MEDICINE (2017)
Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis
Frits R. Rosendaal et al.
BLOOD (2017)
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A
F. Peyvandi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Key insights to understand the immunogenicity of FVIII products
Jenny Goudemand et al.
THROMBOSIS AND HAEMOSTASIS (2016)
The burden of inhibitors in haemophilia patients
Christopher E. Walshl et al.
THROMBOSIS AND HAEMOSTASIS (2016)
Game, set, match for factor VIII mismatch?
Connie H. Miller
BLOOD (2015)
Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity
Johannes Oldenburg et al.
HAEMATOLOGICA (2015)
Development, upscaling and validation of the purification process for human-cl rhFVIII (Nuwiq®), a new generation recombinant factor VIII produced in a human cell-line
Stefan Winge et al.
PROTEIN EXPRESSION AND PURIFICATION (2015)
Inhibitor development in haemophilia according to concentrate Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project
Kathelijn Fischer et al.
THROMBOSIS AND HAEMOSTASIS (2015)
Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity
Johannes Oldenburg et al.
HAEMATOLOGICA (2015)
Factor VIII Products and Inhibitor Development in Severe Hemophilia A
Samantha C. Gouw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII
Christoph Kannicht et al.
THROMBOSIS RESEARCH (2013)
F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis
Samantha C. Gouw et al.
BLOOD (2012)
The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics
Elisabeth Casademunt et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)
F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity
C. H. Miller et al.
HAEMOPHILIA (2012)
Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A
M. E. Mancuso et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII
Helena Sandberg et al.
THROMBOSIS RESEARCH (2012)
Cost of care of haemophilia with inhibitors
Matteo Nicola Dario Di Minno et al.
HAEMOPHILIA (2010)
European Study on Orthopaedic Status of haemophilia patients with inhibitors
M. Morfini et al.
HAEMOPHILIA (2007)
Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A:: the CANAL cohort study
Samantha C. Gouw et al.
BLOOD (2007)
Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A
E. A. Chalmers et al.
HAEMOPHILIA (2007)
Post-translational modifications in the context of therapeutic proteins
Gary Walsh et al.
NATURE BIOTECHNOLOGY (2006)
Risk of inhibitors in haemophilia and the type of factor replacement
Jenny Goudemand et al.
CURRENT OPINION IN HEMATOLOGY (2006)
Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study
E Santagostino et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Appropriate glycosylation of recombinant proteins for human use - Implications of choice of expression system
SA Brooks
MOLECULAR BIOTECHNOLOGY (2004)
Incidence of factor VIII inhibitors in severe haemophilia:: the importance of patient age
JI Lorenzo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
分享论文
